Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, ...
A recent update of this original risk stratification scheme addressed not only recurrence, but also prostate-cancer-specific mortality, in an expanded multicenter database of over 7,000 patients ...
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Nevertheless, MMAI digital histopathology represents an exciting tool with potential to revolutionize risk stratification and treatment selection even in later prostate cancer disease states such as ...
Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...
A new study has identified pathogenic variants in WNT9B as significant risk factors for hereditary prostate cancer. Read more ...
"The scale and scope of data to be presented at the ASCO GU meeting underscore the impact our whole-transcriptome-based Decipher tests are having in treating patients with urologic cancers, and how ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback